Cite
HARVARD Citation
Rushton, M. et al. (n.d.). Optimal dosing of a novel PLK4 inhibitor nested in a phase II study of CFI-400945 in patients with Advanced/Metastatic Breast Cancer (MBC): Canadian Cancer Trials Group (CCTG) IND.237. European journal of cancer. pp. S31-. [Online].